Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development

Gabriel Helmlinger(AstraZeneca (Japan)), Victor Sokolov(Health Decisions (United States)), Kirill Peskov(Sechenov University), Karen Melissa Hallow(University of Georgia), Yuri Kosinsky(Health Decisions (United States)), Veronika Voronova(Health Decisions (United States)), Lulu Chu(AstraZeneca (Japan)), Tatiana A. Yakovleva(Health Decisions (United States)), Ivan Azarov(Health Decisions (United States)), Daniel Kaschek, Artem Dolgun(Health Decisions (United States)), Henning Schmidt, David W. Boulton(AstraZeneca (Japan)), Robert C. Penland(AstraZeneca (Japan))
CPT Pharmacometrics & Systems Pharmacology
May 14, 2019
Cited by 65Open Access
Full Text

Abstract

Quantitative systems pharmacology (QSP), a mechanistically oriented form of drug and disease modeling, seeks to address a diverse set of problems in the discovery and development of therapies. These problems bring a considerable amount of variability and uncertainty inherent in the nonclinical and clinical data. Likewise, the available modeling techniques and related software tools are manifold. Appropriately, the development, qualification, application, and impact of QSP models have been similarly varied. In this review, we describe the progressive maturation of a QSP modeling workflow: a necessary step for the efficient, reproducible development and qualification of QSP models, which themselves are highly iterative and evolutive. Furthermore, we describe three applications of QSP to impact drug development; one supporting new indications for an approved antidiabetic clinical asset through mechanistic hypothesis generation, one highlighting efficacy and safety differentiation within the sodium-glucose cotransporter-2 inhibitor drug class, and one enabling rational selection of immuno-oncology drug combinations.


Related Papers

No related papers found

Powered by citation graph analysis